Zobrazeno 1 - 10
of 67
pro vyhledávání: '"H, Januszewicz"'
Publikováno v:
American journal of hematology. 90(12)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::761189e0dba879bf41f444b62af8dcc4
https://pubmed.ncbi.nlm.nih.gov/26375182
https://pubmed.ncbi.nlm.nih.gov/26375182
Autor:
Henry Miles Prince, Linda Mileshkin, P. Gates, P. Joyce, E. H. Januszewicz, John F. Seymour, Max Wolf
Publikováno v:
Leukemia & Lymphoma. 46:1575-1579
High-dose therapy (HDT) for non-Hodgkins lymphoma (NHL) and multiple myeloma (MM) is considered a feasible option for patients aged 60 years. This study compared the outcomes for all patients aged 60 years treated with HDT at the center to a matched
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::baf44bed9d71adb47ddb40a9a202e775
https://doi.org/10.1080/10428190500235884
https://doi.org/10.1080/10428190500235884
Autor:
E. H. Januszewicz, J. S. White, A. Martinow, Patricia M. Michael, Kathleen C. Rayeroux, Lynda J. Campbell
Publikováno v:
Australian and New Zealand Journal of Medicine. 29:707-712
Background: Philadelphia positive (Ph+) acute lymphoblastic leukaemia (ALL) accounts for 11–29% of adult ALL. Reverse transcriptase polymerase chain reaction (RT-PCR) for the BCR-ABL fusion mRNA has identified patients with the fusion mRNA without
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10160268fd368a1d28d262d40827854d
https://doi.org/10.1111/j.1445-5994.1999.tb01619.x
https://doi.org/10.1111/j.1445-5994.1999.tb01619.x
Publikováno v:
Internal medicine journal. 42(7)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e68ff79e7d3f1235fb7d2f00a943a1aa
https://pubmed.ncbi.nlm.nih.gov/22805693
https://pubmed.ncbi.nlm.nih.gov/22805693
Publikováno v:
Australian and New Zealand Journal of Medicine. 29:556-558
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2a35cae3ef0e330bf827f0180214a5d
https://doi.org/10.1111/j.1445-5994.1999.tb00758.x
https://doi.org/10.1111/j.1445-5994.1999.tb00758.x
Autor:
G A, Kennedy, J F, Seymour, M, Wolf, H, Januszewicz, J, Davison, C, McCormack, G, Ryan, H M, Prince
Publikováno v:
European journal of haematology. 71(4)
Alemtuzumab (anti-CD52, Campath-1H) has recently been shown to be effective in the treatment of a range of hematological malignancies, including B-cell chronic lymphocytic leukemia and T-cell prolymphocytic leukemia. We undertook a phase II study to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5a43ba802987ae61801fa644a4b76c89
https://pubmed.ncbi.nlm.nih.gov/12950233
https://pubmed.ncbi.nlm.nih.gov/12950233
Publikováno v:
Leukemialymphoma. 43(9)
Central nervous system (CNS) relapse of non-Hodgkin's lymphoma (NHL) is usually fatal despite therapy and effective prophylaxis is desirable. Patients at high-risk usually receive intrathecal (i.t.) prophylaxis, although its efficacy is unproven. We
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a935812630b12fb8c0f5c9a816cfdab
https://pubmed.ncbi.nlm.nih.gov/12685832
https://pubmed.ncbi.nlm.nih.gov/12685832
Autor:
David Gottlieb, Simon Durrant, Jane P. Matthews, Lindsay Dunlop, Paul Cannell, John Bashford, Ray M. Lowenthal, Kerry Taylor, Heather Baxter, Paul Eliadis, Anthony P. Schwarer, Michael F. Leahy, Graham A.R. Young, Douglas E. Joshua, Christopher Arthur, Devinder Gill, A Enno, Timothy A. Brighton, H Januszewicz, A Gillett, Kenneth F. Bradstock
Publikováno v:
Leukemia. 15(9)
The Australian Leukaemia Study Group (ALSG) investigated whether G-CSF would accelerate haemopoietic recovery after induction treatment for acute myeloid leukaemia (AML) intensified with high-dose cytarabine, and therefore improve response rates and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e43185d7a26aac2cfa4439aa5f7043f
https://pubmed.ncbi.nlm.nih.gov/11516093
https://pubmed.ncbi.nlm.nih.gov/11516093
Autor:
A. J. Dowling, E. H. Januszewicz, A. Wirth, J. G. Smith, H. M. Prince, Surender Juneja, P. Gates, John F. Seymour, M. Wolf
Publikováno v:
Internal medicine journal. 31(5)
Background: High-dose therapy (HDT) with autologous bone marrow or blood cell transplantation for the treatment of lymphoma commenced at Peter MacCallum Cancer Institute in 1986. Aim: To examine the patient characteristics and outcomes of patients wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea790792d7304ac58997de466efaa987
https://pubmed.ncbi.nlm.nih.gov/11512599
https://pubmed.ncbi.nlm.nih.gov/11512599
Autor:
Michael A. Quinn, Max Wolf, I Bertoncello, C. Seymour, J Gardyn, Surender Juneja, Henry Miles Prince, P Chapple, H Januszewicz, D. Venter, M Brettell
Publikováno v:
Bone marrow transplantation. 22(2)
A reliable measure to predict peripheral blood progenitor cell (PBPC) autograft CD34+ cell content is required to optimize the timing of PBPC collection. We prospectively examined the peripheral blood (PB) CD34+ cell count in 59 consecutive patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93059b991714b8e5546df74f39c3599e
https://pubmed.ncbi.nlm.nih.gov/9707018
https://pubmed.ncbi.nlm.nih.gov/9707018